Mumbai (Maharashtra) [India], February 11 (ANI/PNN): JB Pharma, one of the fastest-growing pharmaceutical companies in India, announced record revenue growth of 32 per cent to Rs 793 crore in Q3 FY23.
The Adani group company on Wednesday announced the financial results for the December-ended quarter and the first three quarters of the current financial year 2022-23
The Adani group company on Wednesday announced the financial results for the December-ended quarter and the first three quarters of the current financial year 2022-23.
The Adani group company's revenue from operations increased 18 per cent to Rs 4,786 crore during the December quarter. In the same quarter of 2021, the revenue was Rs 4,072.
The Adani group company's profit after tax rose 73 per cent on a yearly basis to Rs 478 crore during the December quarter. In the same quarter of 2021, the profits were Rs 277 crore.
Citi, CLSA, and Goldman Sachs have recommended to buy the share post-Q3FY23 earnings, while Bank of America (BofA) maintained its 'neutral' rating. Goldman believes that Paytm's current share price continues to offer a compelling entry point into India's largest fintech platforms.
Union Finance Minister Sitharaman also announced a new sub-scheme named Pradhan Mantri Matsya Kisan Samridhi Sah-Yojana (PM-MKSSY): Central Sector Sub-scheme under PMMSY with targeted investment of Rs 6,000 crore with the objective to enhance further the earnings and incomes of fishermen,